Professional Career
01.7.2012 to present Professor and Chairman; Department of Psychiatry and Psychotherapy
Ludwig-Maximilians-University Munich
01.08.2006- 30.6.2012 Professor and Chairman; Department of Psychiatry and Psychotherapy
University of Göttingen, Germany
01.08.2002 – 31.07.2006 Professor and Chairman; Department of Psychiatry and Psychotherapy
University of Saarland, Homburg/Saar (Germany)
Awards
- Kurt-Schneider-Preis 2015; Award supported with 10.000€
- Kraepelin-Award 2004, with a support of 7.500€
- Various Stanley Award Centre Grants
Scientific Societies – Memberships
| 2021-2023 | President of the European Psychiatric Association (EPA) |
| 2019-2023 | Senator of the Leopoldina Akademie der Wissenschaften |
| 2018-2022 | Vice-President of the World Federation of Societies of Biological Psychiatry (WFSBP) |
| 2018-2021 | Vice-President of the Arbeitsgemeinschaft Wissenschaftlich Medizinischer Fachgesellschaften (AWMF) |
| 2013-2014 | Section chief of the Council of National Societies (NPAs) der European Psychiatric Association (EPA) |
| 2011-2012 | President of the Deutsche Gesellschaft für Psychiatrie und Psychotherapie (DGPPN) (Board member since 1995) |
| 2007-2010 | President of the Deutsche Gesellschaft für Biologische Psychiatrie (DGBP) |
| Memberships: Leopoldina Akademie der Wissenschaften; Collegiate of the Deutschen Forschungsgemeinschaft (DFG) 2010 – 2018; Deutsche Gesellschaft für Neurogenetik e.V. (DGNG); Europäische Arbeitsgemeinschaft Gerontopsychiatrie (EAG); Arbeitsgemeinschaft für Neuropsychopharmakologie (AGNP); Neurowissenschaftliche Gesellschaft (NWG); Schizophrenia International Research Society (SIRS). |
Scientific Activities
- Membership in Editorial/Advisory Boards (i.e. Chief-Editor – European Archives of Psychiatry and Clinical Neuroscience, Springer; Co-Editor Schizophrenia Bulletin)
- Reviewer for scientific journals (i.e. Biol Psychiatry, JAMA Psychiatry, Mol Psychiatry, Am J Psychiatry, Schizophr Bull, Schizophr Res, Transl Psychiat, World J Biol Psychiatry, Lancet)
- Expert for funding institutions with peer-review procedure – Total Research Support funding since 1994: 15.000.000 EUR.
Current funding:
- Falkai P: ESPRIT: Enhancing schizophrenia prevention and recovery by innovative treatments; Aerobic exercise for the improvement of cognition and enhancement of recovery in post-acute schizophrenia. BMBF (01EE1407E). 02/2015-01/2021: 471.013 €
- Binder E, Falkai P. International Max Planck Research School on Translational Psychiatry (IMPRS-TP) Max-Planck-Society 01/2016-12/2021: 1.950.000 €
- Falkai P. Robert-Vogel-Stiftung: Frühprädiktion und Frührehabilitation von jungen Menschen mit schizophrenen und affektiven Erkrankungen (CHANCE). 2016-2021: 1.500.000 €
- Hasan A, Falkai P. Add-on spironolactone for the treatment of schizophrenia (SPIRO-TREAT), EUDRACT: 2014-001968-35. Stanley Foundation 11/2014-06/2020: 250.000 €
- Falkai P, Binder E. EKF Forschungskolleg “Translationale Psychiatrie”. Else Kröner-Fresenius Stiftung 10/2017-09/2020; 1.000.000 €. Extension 2020-2023; 1.000.000€
- Prolongation E K F Forschungskolleg “Translationale Psychiatrie” (PI, Else Kröner-Fresenius-Stiftung, 2020-2023, 1.000.000€)
- DFG Graduiertenkolleg „POKAL“, 2021-2026; 600.000€
- Innofond „SISYPHOS“, 2021-2024; 400.000€
Publications:
• Web of Science Hirsch-Index: 80; Total publications: 954 (as of 22.03.2022)
• Creator of treatment guidelines for schizophrenia for the WFSBP; Creator of S3 treatment guidelines for the DGPPN
• Books published: 30